Neuraxis, INC
NRXS NYSE· Electromedical & Electrotherapeutic Apparatus
Last close · Oct 26, 2026
$7.25
KIRA · Stoqly’s AI analyst, in plain words
- Neuraxis, INC had $3.6M of revenue in fiscal 2025, up 32.9% on the year before.
- Its operating margin was −219.4%, up 47.1 pts: of every 100 in sales, about −219 is left after running the business.
- Neuraxis, INC lost $7.8M in fiscal 2025.
- Free cash flow was −$6.5M in fiscal 2025, −181.1% of revenue.
- Neuraxis, INC has $4.8M more cash than debt.
Market cap
$87.9M
P/E
—
Revenue
$3.6M
Net income
−$7.8M
Free cash flow
−$6.5M
Operating margin
−219.4%
Neuraxis, INC in 30 seconds · fiscal 2025
Are sales growing?
+32.9%
Yes. Sales grew 32.9% last year.
Does it make a profit?
−218.5%
No. It lost money last year.
Does profit turn into cash?
−181.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Neuraxis, INC does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Neuraxis, INC
- CIK
- 0001933567
Neuraxis, INC · NRXS
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $2.7M | $2.5M | $2.7M | $3.6M |
| Revenue growth | — | −8.4% | 9.2% | 32.9% |
| Gross margin | 88.9% | 87.7% | 86.5% | 84.2% |
| Operating margin | −125.6% | −270.9% | −266.5% | −219.4% |
| Net income | −$4.8M | −$14.6M | −$8.2M | −$7.8M |
| Net margin | −178.0% | −594.6% | −306.8% | −218.5% |
| Diluted EPS | −$2.77 | −$4.50 | −$1.22 | −$0.95 |
| Cash | ||||
| Cash from operations | −$2.3M | −$6.7M | −$6.1M | −$6.4M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$2.3M | −$6.7M | −$6.1M | −$6.5M |
| FCF margin | −85.6% | −273.4% | −228.1% | −181.1% |
| Share count change | — | 62.3% | 112.7% | 31.3% |
| Debt and strength | ||||
| Cash and short-term investments | $0.3M | $0.1M | $3.7M | $5.0M |
| Debt incl. finance leases | $0.2M | $0.1M | $0.2M | $0.1M |
| Deposits | $0.1M | $0.1M | $0.0M | $0.0M |
| Shareholders' equity | −$5.6M | −$1.4M | $2.1M | $3.4M |
| Current ratio | 0.1x | 0.1x | 1.8x | 2.1x |
| Interest coverage | −10.6x | −14.0x | −41.1x | −105.8x |
| Returns and quality | ||||
| Return on equity | — | — | −2,480.5% | −285.4% |
| Return on tangible equity | — | — | −428.8% | −275.7% |
| Piotroski F-score | — | 3 | 4 | 4 |
| Altman Z'' | −119.6 | −420.5 | −45.7 | −36.9 |
Insiders bought, 12 months
$1.4M
5 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Neuraxis, INC · NRXS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.25 a share, the company is worth $87.9M.
Source: SEC EDGAR XBRL filings (CIK 0001933567). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.